USANA HEALTH SCIENCES (USNA) Company Report

USANA Health Sciences projects mid-single-digit sales growth for 2026, aiming for nearly $1 billion in revenue, with a significant portion of this growth driven by its M&A offerings outside the core business.
The Rise Wellness acquisition is a key growth driver, with projected revenue of $65-$80 million in 2026, up from $16 million in 2025 and $5 million in 2024, largely due to the success of its Protein Pop product and expansion into major retailers like Target and Costco.
The HYA acquisition is also contributing significantly, with expected revenue of $140-$155 million in 2026, up from $132 million in 2025, supported by entry into retail channels and expansion into Canada and the United Kingdom in Q1.
The non-direct selling (omnichannel) portion of the business is rapidly growing, projected to account for low 20s% of total revenue in 2026, compared to approximately 16% in 2025 and being negligible in 2024.
Kevin Guest has transitioned back into the CEO role to reinvigorate the core direct selling business, which faces challenges and is expected to be down mid-single digits in 2026, with cost alignment initiatives planned for rollout on February 17th.

3 days ago

Transcript

USANA Health Sciences Discusses 2026 Outlook and Strategic Growth Drivers

USNA

Guidance Update

M&A

CEO Change

USANA Health Sciences anticipates mid-single-digit growth for 2026, targeting nearly $1 billion in revenue, with a significant portion of this growth coming from outside its core business.
The Rise Wellness segment is projected to grow from over $16 million in 2025 to between $65 million and $80 million in 2026, largely due to the success and expanded distribution of Protein Pop in retailers like Target and Costco.
The Hiya segment is expected to reach $140 million to $155 million in 2026, up from an estimated $132 million in 2025, driven by entry into retail channels and expansion into Canada and the United Kingdom in Q1 2026.
The non-direct selling portion of the business is forecasted to contribute 16% of revenue in 2025, increasing to the low 20s% in 2026.
Kevin Guest was recently appointed as the new CEO, returning to the role to reinvigorate the core direct selling business.

3 days ago

Transcript

USANA Health Sciences Provides Preliminary FY 2025 Net Sales and Initial FY 2026 Outlook

USNA

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

USANA Health Sciences reported preliminary fiscal year 2025 net sales of approximately $925 million, surpassing its most recent guidance of $920 million.
The company provided an initial fiscal year 2026 net sales outlook ranging from $925 million to $1.0 billion.
This 2026 outlook projects sales of $720 to $765 million for the core nutritional business, $140 to $155 million for Hiya, and $65 to $80 million for Rise Wellness.
Rise Wellness is expected to experience accelerated growth in fiscal 2026, with operating margins projected to be at breakeven due to strategic investments.

3 days ago

8-K

USANA Provides Preliminary FY 2025 Net Sales and Initial FY 2026 Outlook

USNA

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

USANA Health Sciences announced preliminary fiscal year 2025 consolidated net sales of approximately $925 million, which is ahead of its most recently issued guidance of $920 million.
The company issued an initial net sales outlook for fiscal year 2026 in the range of $925 million to $1.0 billion.
This 2026 outlook includes net sales from its core nutritional business (USANA) of $720 to $765 million, Hiya of $140 to $155 million, and Rise Wellness of $65 to $80 million.
Fiscal year 2026 is a 52-week year, which means one less week of net sales compared to fiscal 2025, impacting the core nutritional business.
USANA is making meaningful investments in inventory, capital expenditures, and working capital to support the early growth stages of Rise Wellness and Hiya.

3 days ago

Press Release

USANA Health Sciences Announces CEO Transition

USNA

CEO Change

Management Change

Kevin Guest has returned to USANA Health Sciences, Inc. as Chief Executive Officer, effective January 8, 2026, and will continue to serve as Chairman.
Jim Brown has stepped down from his position as CEO and President, but will remain with the Company in an advisory role.
Mr. Guest previously served as CEO from 2015 to 2023 and as Executive Chairman for the past three years.
The Compensation Committee has not yet determined the material terms of compensation for either Mr. Brown or Mr. Guest in connection with these changes.

7 days ago

8-K

USANA Health Sciences Announces Kevin Guest's Return as CEO

USNA

CEO Change

Management Change

Kevin Guest has returned to USANA Health Sciences as Chief Executive Officer, effective immediately, and will continue to serve as Chairman.
This leadership transition includes the departure of Jim Brown from his roles as CEO and President.
Mr. Guest previously served as CEO for eight years, from 2015 to 2023, during which he oversaw global expansion and strengthened operational performance.
The Board believes this change will accelerate strategic priorities to contribute to long-term growth and enhance shareholder value.

7 days ago

Press Release

USANA Health Sciences Discusses Strategic Diversification and Hiya Health Acquisition

USNA

M&A

New Projects/Investments

Revenue Acceleration/Inflection

USANA Health Sciences, a global manufacturer and distributor of science-based nutritional and personal care products, primarily operates through direct sales and is expanding its direct-to-consumer (DTC) channel.
The company acquired Hiya Health products in December 2024, a fast-growing leader in children's health and wellness, to diversify its distribution channels, expand its domestic presence, and enter the broader DTC wellness market.
USANA reported no debt as of the end of the third quarter and maintains healthy free cash flow, with capital allocation priorities focused on internal investments for organic growth and share repurchases.
Future growth initiatives include expanding Hiya's product portfolio, distribution into retail and Amazon, and international geographic footprint, with plans to bring Hiya's manufacturing in-house starting in 2026 to improve gross margins and operational efficiency.

Dec 11, 2025, 3:00 PM

Transcript

USANA Health Sciences Discusses Strategic Initiatives and Hiya Acquisition

USNA

M&A

New Projects/Investments

Demand Weakening

USANA Health Sciences (USNA) manufactures and distributes nutritional and personal care products, operating through both direct sales and a growing direct-to-consumer channel.
The company acquired Hiya Health products in December 2024, a children's health and wellness brand, to expand its direct-to-consumer market presence and strengthen its financial profile.
As of the end of the third quarter, USANA reported no debt and healthy free cash flow.
USANA plans to bring Hiya's currently outsourced production in-house starting in 2026, which is anticipated to improve gross margins.
While the direct selling business has experienced some top-line downward trends, Hiya is expanding its distribution into retail and Amazon, with USANA supporting its international growth.

Dec 11, 2025, 3:00 PM

Transcript

USANA Health Sciences Reports Q3 2025 Results and Strategic Updates

USNA

Guidance Update

Revenue Acceleration/Inflection

Layoffs

USANA Health Sciences' Q3 2025 results were impacted by softer sales and brand partner productivity leading up to the global convention in August. However, management is encouraged by recent activity following the full rollout of its enhanced compensation plan in July.
The company is seeing positive early indications from the new compensation plan, including improved engagement, brand partner attraction, and customer acquisition, particularly in mature markets like the United States.
USANA has initiated a global cost reduction process, including a right-sizing of its workforce, and expects to incur an estimated one-time charge of $4.7 million in the fourth quarter.
Venture companies Hiya Health and RiseBar showed strong year-to-date growth, with Hiya Health delivering 26% year-to-date sales growth and RiseBar's year-to-date net sales increasing 169%. Hiya Health is expected to generate double-digit sales growth for the full 2025.

Oct 23, 2025, 3:00 PM

Transcript

USANA Health Sciences Discusses Q3 2025 Performance and Strategic Initiatives

USNA

Guidance Update

Layoffs

New Projects/Investments

USANA Health Sciences reported that Q3 2025 results were impacted by softer sales and brand partner productivity; however, the company observed promising trends in sales activity and leader productivity following the global rollout of its enhanced compensation plan in August.
The company initiated a global cost reduction process, including workforce right-sizing, anticipating an estimated one-time charge of $4.7 million in Q4.
Its direct-to-consumer business, Hiya, achieved 26% year-to-date sales growth and is projected to deliver double-digit sales growth for the full 2025, despite experiencing top-line growth challenges in Q3.
Rise Bar, another venture company, reported record third-quarter net sales and a 169% increase in year-to-date net sales.
USANA is committed to a diversification strategy, investing in Hiya and Rise Bar, and exploring additional M&A opportunities to expand its omnichannel presence.